Project Grant R21AI203022
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $237K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Notre Dame, IN 46556, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $838,493 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to optimize human cytomegalovirus neutralizing monoclonal antibodies as therapeutic biologics. The research characterizes pre-clinical parameters for developing human CMV neutralizing monoclonal antibodies targeting envelope proteins as therapeutics to inhibit CMV infection and...
- The National Institute of Allergy and Infectious Diseases awarded San Diego Biomedical Research Institute $992,920 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research on nanoscale imaging of cell surface HIV envelope immune complexes to optimize natural killer cell antibody-dependent cellular cytotoxicity (ADCC) therapeutics. The project integrates nanoscale imaging, machine learning, and in silico protein modeling to characterize the...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame $614,655 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate bladder inflammatory and immune responses to fungal catheter-associated urinary tract infections caused by Candida albicans. The research addresses a significant knowledge gap in understanding fungal catheter-associated urinary tract infections, which now represent the second leading...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame $434,500 on August 1, 2026, under CFDA 93.855 (Allergy and Infectious Diseases Research) to conduct genomic and serological research distinguishing imported from locally transmitted malaria in the Ethiopian highlands. The recipient will sequence over 1,000 Plasmodium falciparum and over 800 P. vivax samples collected since 2019 to assess whether imported infections spread in the highlands, whether...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame DU Lac $709,532 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct systematic research into the cytoplasmic pathway for peptidoglycan recycling in Pseudomonas aeruginosa, an antibiotic-resistant gram-negative bacterial pathogen responsible for recurrent lung infections in cystic fibrosis patients. The work addresses two specific aims. The first...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded $148,614 to Massachusetts Institute of Technology on January 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop glycopolymers designed to enhance interactions between immune cells and pathogenic bacteria, creating "cellular glues" that leverage the body's innate immune mechanisms as an alternative to...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3.05 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Virginia on September 12, 2025, with a completion date of August 31, 2029. This research initiative investigates paired receptor signaling in natural killer (NK) cells to understand antiviral immunity and viral control mechanisms. The project employs advanced molecular...
- The National Institute of Allergy and Infectious Diseases awarded Drexel University $624,806 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and characterize nanotrap therapeutic vaccines for HIV treatment. The project, titled "Nanotrap Therapeutic Vaccines for HIV Virion Capture and Infected Cell Targeting" (R01AI203404), will engineer liposomal nanoparticles displaying multivalent CD4 mimetic ligands designed to capture...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame Du Lac $197,500 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how tyloxapol inhibits mycobacterial type VII secretory activity. The research addresses the molecular mechanisms by which tyloxapol, a non-ionic detergent, impairs the ESX-1 secretion system essential for mycobacterial infection. Preliminary data demonstrate that sub-critical...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $33,116,067 Cooperative Agreement to the University of California, Irvine (UCI) for the "Allergy and Infectious Diseases Research" program (CFDA 93.855). The award, titled "The UCI Vaccines for Pandemic Preparedness Center (VPPC)", aims to conduct basic and translational research to develop prototype vaccines against emerging viruses. The project will characterize and compare two universal,...